University of Alabama at Birmingham, Birmingham, Alabama.
Sanofi, Cambridge, Massachusetts.
Arthritis Care Res (Hoboken). 2024 Feb;76(2):181-190. doi: 10.1002/acr.25223. Epub 2023 Nov 13.
An interactive tool identifying treatment attributes important to patients can enhance shared decision-making (SDM) in rheumatoid arthritis (RA). A formative survey was conducted to identify the most important treatment attributes from patients' perspective, which can be used to develop an interactive SDM tool.
The survey was performed in two phases: qualitative interviews and quantitative surveys. The qualitative interviews were conducted to inform the design of the quantitative survey. In qualitative interviews, patients with RA (n = 10) and rheumatologists (n = 10) were introduced to the SDM tool concept. Feedback on the design and scope of the SDM tool was used to develop a quantitative survey, conducted in a large sample size of patients. Patient preferences for treatment attributes (route of administration and dosing frequency, serious side effects, out-of-pocket costs, efficacy, and monitoring requirement) were assessed via adaptive conjoint exercise involving ranking of hypothetical RA treatment configurations.
A total of 944 patients (males: 43%, females: 57%) with RA participated in the quantitative survey. Route of administration and dosing frequency (38%) followed by serious side effects (33%) were the two most important treatment attributes for individual patients. The recontact survey (n = 172/944) estimated tool stability of 72% (n = 124/172) in terms of the relative importance of treatment attributes.
The findings of this survey could be used in the development of an SDM tool that can potentially provide insights into patient preferences and is generally well received by patients and rheumatologists with good agreement and reliability.
一种能够识别对患者重要的治疗属性的交互式工具可以增强类风湿关节炎(RA)的共同决策(SDM)。进行了一项形成性调查,以从患者的角度确定最重要的治疗属性,这些属性可用于开发交互式 SDM 工具。
该调查分两个阶段进行:定性访谈和定量调查。定性访谈用于为定量调查的设计提供信息。在定性访谈中,向 10 名 RA 患者和 10 名风湿病医生介绍了 SDM 工具的概念。关于 SDM 工具的设计和范围的反馈用于开发一项大型患者样本的定量调查。通过涉及假设 RA 治疗方案的排序的自适应联合练习评估患者对治疗属性(给药途径和给药频率、严重副作用、自付费用、疗效和监测要求)的偏好。
共有 944 名 RA 患者(男性:43%,女性:57%)参加了定量调查。给药途径和给药频率(38%)其次是严重副作用(33%)是每位患者最重要的两个治疗属性。再联系调查(n=172/944)估计工具稳定性为 72%(n=124/172),在治疗属性的相对重要性方面。
这项调查的结果可用于开发 SDM 工具,该工具可以深入了解患者的偏好,并且通常会受到患者和风湿病医生的好评,具有良好的一致性和可靠性。